CD19 CAR T-Cell Therapy for Refractory Ulcerative Colitis

CD19 CAR T-Cell Therapy for Refractoryyears, the therapeutic armamentarium for ulcerative colitis (UC) has expanded considerably, largely because of the development of biologics and small molecules targeting key effector mediators involved in disease pathogenesis.Despite these advances, a subset of patients remains resistant to all currently available therapies, ultimately requiring colectomy.In the New England Journal of Medicine, Mller and colleagues 1 reported a case of a 21-year-old patient with severe UC resistant to multiple pharmacologic therapies who achieved stable clinical, endoscopic, and histologic remission following administration of autologous chimeric antigen receptor (CAR) T cells targeting CD19.CD19 is a transmembrane protein expressed on both normal and malignant B cells that function as a coreceptor for the B-cell receptor, amplifying intracellular signaling pathways that regulate B-cell activation and responses. [2][3]][4]